For R&D scientists and formulation experts in the pharmaceutical industry, a deep understanding of the technical characteristics of active pharmaceutical ingredients (APIs) and intermediates is crucial for successful product development. Armillarisin A (CAS 53696-74-5) is one such compound, valued for its specific physiochemical properties and therapeutic applications. This overview aims to provide a technical perspective on Armillarisin A, focusing on its properties and considerations for pharmaceutical formulations.

Armillarisin A is typically supplied as a yellow to orange crystalline powder. Its insolubility in water, yet slight solubility in ethanol and methanol, dictates its formulation strategies. For oral administration, excipients that enhance solubility or facilitate absorption, such as solubilizers or micronization techniques, may be employed. The compound's melting point, in the range of 253-255°C, indicates its thermal stability under standard processing conditions, which is beneficial during manufacturing.

The molecular formula C12H10O5 and molecular weight of approximately 244.21 g/mol are fundamental for stoichiometric calculations in formulation and dosage determinations. A common quality standard for Armillarisin A is pharmaceutical grade, with a minimum purity of 98%. This high purity is essential to minimize potential impurities that could affect the safety and efficacy of the final drug product. When sourcing from manufacturers, detailed analytical data, including HPLC chromatograms and impurity profiles, are invaluable for quality assurance.

When developing formulations for Armillarisin A, particularly for its applications in cholecystitis and gastritis management, formulators must consider its therapeutic targets. Its ability to relieve biliary tract sphincter spasms and reduce inflammation suggests routes of administration and dosage forms that maximize local or systemic delivery to affected areas. For instance, solid dosage forms like tablets or capsules are common, requiring compatibility studies with various pharmaceutical excipients such as binders, disintegrants, and lubricants.

Furthermore, understanding the stability profile of Armillarisin A under different storage conditions is critical. While generally stable, specific requirements for dry, dark storage at controlled temperatures, as often recommended by suppliers, should be rigorously followed to maintain its potency over its shelf life. Any formulator or procurement manager looking to buy Armillarisin A should engage with their chosen manufacturer to obtain comprehensive technical data and formulation guidance, ensuring optimal outcomes.